MHRA Approves YORVIPATH In Great Britain For Adults With Chronic Hypoparathyroidism
MHRA Approves YORVIPATH In Great Britain For Adults With Chronic Hypoparathyroidism
MHRA批准在英國爲患有慢性甲狀旁腺功能減退的成年人提供YORVIPATH
MHRA Approves YORVIPATH In Great Britain For Adults With Chronic Hypoparathyroidism
MHRA批准在英國爲患有慢性甲狀旁腺功能減退的成年人提供YORVIPATH
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。